OsteoVes Partially Restored Mineral Deposition and Mechanical Signaling in Aging Bone Tissue
OsteoVes Partially Restored Mineral Deposition and Mechanical Signaling in Aging Bone Tissue
On August 18, Cell Reports Medicine published a study of OsteoVes, engineered particles designed to restore mineral deposition and mechanical signaling in aging bone tissue. In experiments involving cells from older donors, aged mice, and three macaques, OsteoVes shifted measured outcomes toward bone formation.
Bone marrow mesenchymal stromal cells can become either bone-forming cells or adipose tissue cells. The extracellular matrix, which consists of proteins and minerals surrounding the cell, influences this choice. With age, the matrix becomes less effective at depositing minerals and transmitting mechanical signals to the cell.
Several authors of the new study had already modified the mechanical properties of the environment following bone injury in 2025. A hydrogel mimicked a blood clot and helped cells activate a bone formation program. They have now tested whether temporarily replacing matrix functions can also direct bone marrow cells toward bone formation in aging tissue.
In their Cell Reports Medicine article, the authors described OsteoVes, particles that mimic bone matrix vesicles. Their alkaline phosphatase breaks down pyrophosphate, which inhibits mineralization. Hydroxyapatite nanoparticles, composed of a mineral found in bone tissue, provide a starting point for mineral deposition, while a membrane coating retains the construct within the extracellular matrix.
The authors compared the complete construct with its individual components. In aged human stromal cells, OsteoVes increased the formation of mineralized matrix and the activity of genes associated with bone formation. Constructs lacking either the enzyme or hydroxyapatite, as well as empty membrane vesicles, had weaker effects. The effect also weakened when the researchers blocked PIEZO1, a channel protein that helps cells respond to mechanical forces. This result linked the change in the mineralized environment to the cell's mechanical response.
The researchers then tested whether OsteoVes altered bone tissue in aged animals. In 22-month-old mice, two intravenous doses administered one week apart increased the maximum load that the femur could withstand by approximately 1,4-fold by the fourth week. Bending strength increased by approximately 95% compared with the saline control. Three 13-year-old female macaques with hyperglycemia and impaired lipid metabolism received two doses. After four weeks, micro-CT showed an increase of approximately 4% in bone mineral density, 10% in bone volume fraction, and 24% in the number of trabeculae, the internal struts of bone.
The authors restored mineralization and particle retention within the matrix, observed a cellular response, and then measured bone tissue in aged animals. OsteoVes tests whether repairing the age-altered environment around stromal cells can restore the functions required for bone formation.